BIO.News Newsletter

Today, we have a quick recap of yesterday’s Senate hearing on the federal COVID-19 response, plus a look at a must-read long-read on how the tide is turning on GMOs and why it matters. (842 words, 4 minutes, 12 seconds)

Today, we look at a recent report that has both good and bad news on cancer deaths in the U.S., as well as how gene editing can make biryani ingredients more sustainable and resilient. (772 words, 3 minutes, 51 seconds)

We start a new week bearing bad news: COVID cases are rising across the U.S., and extreme climate events are increasing around the world. Fortunately, biotech can deliver solutions to both challenges—but we have some work to do to get them where they need to go. (766 words, 3 minutes, 49 seconds)

Closing the week with a promising bipartisan bill that would establish an out-of-pocket cap for Medicare Part D beneficiaries, as well as USDA’s nominee to oversee marketing and regulatory programs. Plus—we have an inspiring new I am BIO video to start your weekend right. (851 words, 4 minutes, 31 seconds)

Ahead of German Chancellor Angela Merkel’s visit to Washington, BIO sent a letter to her government about how we can collaborate on global vaccine access—we have the scoop. Plus, LanzaTech has a new partnership to produce clothing from carbon. (1,000 words, 5 minutes)

Last week, the U.S. Trade Representative met with Mexican government officials to discuss Mexico’s policy toward biotech crops—we have the readout, plus insights from yesterday’s Senate Judiciary hearing on competition policy for prescription drugs. (807 words, 4 minutes, 2 seconds)

Today, we have a deep dive into a new report on the regulatory framework for gene editing of agricultural animals, as well as three concrete things your company can do right now to improve diversity, equity, and inclusion in the biotech industry. (819 words, 4 minutes, 5 seconds)

We’re back! Today, we look at how far we’ve come on COVID vaccinations and the sustainable aviation fuel legislation we’re watching as Congress returns to the Capitol. We also have headlines you might have missed over the break, plus what to expect this week in Washington. (945 words, 4 minutes, 43 seconds)

Like many of you, Team Good Day BIO is taking a break to enjoy summer—but don’t worry, we’ll be back in your inbox on Monday, July 12, to ensure you don’t miss a beat. In the meantime, if you need something to read or listen to at the beach, by the pool, or just away from your desk, here’s what’s on our list. Take a look and stay on top of the latest biotech news—because there’s a lot to do when we get back. 

Before you head out for the holiday weekend, we have an update on FY22 funding for USDA and FDA, as well as a recap of BIO’s Clinical Trial Diversity Summit with practical things we can do right now to improve trial diversity. (813 words, 4 minutes, 3 seconds) BIO is taking a break for the Fourth of July. Good Day BIO will resume regular publication on Monday, July 12. Enjoy your time with family and friends—and if you haven’t done so yet, it’s a great time to get your COVID vaccine!